id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-E-0161-0006,FDA,FDA-2025-E-0161,Determination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH,Notice,Determinations,2026-02-26T05:00:00Z,2026,2,2026-02-26T05:00:00Z,2026-04-28T03:59:59Z,2026-02-26T20:55:38Z,2026-03848,1,0,09000064b91deb09
FDA-2025-E-0161-0005,FDA,FDA-2025-E-0161,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-12-02T05:00:00Z,2025,12,2025-12-02T05:00:00Z,,2025-12-03T02:27:37Z,,0,0,09000064b90aa311
FDA-2025-E-0161-0004,FDA,FDA-2025-E-0161,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-11-05T05:00:00Z,2025,11,2025-11-05T05:00:00Z,,2025-11-05T22:27:33Z,,0,0,09000064b9069679
FDA-2025-E-0161-0003,FDA,FDA-2025-E-0161,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-09-26T04:00:00Z,2025,9,2025-09-26T04:00:00Z,,2025-11-05T18:01:02Z,,0,0,09000064b8fdf76c
FDA-2025-E-0161-0002,FDA,FDA-2025-E-0161,"Patent Extension Application from Cooley LLP (on behalf of Pfizer, Inc)",Other,Application,2025-01-15T05:00:00Z,2025,1,2025-01-15T05:00:00Z,,2025-01-15T21:15:24Z,,0,0,09000064868bcb1c
FDA-2025-E-0161-0001,FDA,FDA-2025-E-0161,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-01-15T05:00:00Z,2025,1,2025-01-15T05:00:00Z,,2025-01-15T21:15:18Z,,0,0,09000064868bcb1a